A proposed role for efflux transporters in the pathogenesis of hydrocephalus

Hydrocephalus is a common brain disorder that is treated only with surgery. The basis for surgical treatment rests on the circulation theory. However, clinical and experimental data to substantiate circulation theory have remained inconclusive. In brain tissue and in the ventricles, we see that osmotic gradients drive water diffusion in water-permeable tissue. As the osmolarity of ventricular CSF increases within the cerebral ventricles, water movement into the ventricles increases and causes hydrocephalus. Macromolecular clearance from the ventricles is a mechanism to establish the normal CSF osmolarity, and therefore ventricular volume. Efflux transporters, (p-glycoprotein), are located along the blood brain barrier and play an important role in the clearance of macromolecules (endobiotics and xenobiotics) from the brain to the blood. There is clinical and experimental data to show that macromolecules are cleared out of the brain in normal and hydrocephalic brains. This article summarizes the existing evidence to support the role of efflux transporters in the pathogenesis of hydrocephalus. The location of p-gp along the pathways of macromolecular clearance and the broad substrate specificity of this abundant transporter to a variety of different macromolecules are reviewed. Involvement of p-gp in the transport of amyloid beta in Alzheimer disease and its relation to normal pressure hydrocephalus is reviewed. Finally, individual variability of p-gp expression might explain the variability in the development of hydrocephalus following intraventricular hemorrhage.
Hydrocephalus is a common brain disorder that affects children and individuals of all ages. It is the most common congenital abnormality in children (one out of 500 births) (1). If left untreated, hydrocephalus can lead to permanent brain damage and result in cognitive and physical handicap.

Contemporary surgical management of hydrocephalus is based on the popular conceptualization of circulation theory. The circulation theory of hydrocephalus states that cerebrospinal fluid (CSF) produced by the choroid plexus flows along specific pathways to be absorbed by the venous sinuses. An obstruction in any part of these pathways leads to hydrocephalus. Surgical management of hydrocephalus is therefore directed at detecting and removing the source of obstruction (such as removal of tumor or blockage of pathways) or diverting the fluid bypassing the obstruction. As such, the most common treatment for hydrocephalus is the surgical implantation of a shunt system to divert the flow of CSF from the ventricles. However, although most cases of hydrocephalus are managed with a shunt system, it is rare for the device to last a lifetime without complications. Treatment of hydrocephalus leads to approximately 38,000 admissions per year in the US. Costs for treatment range from US $1.4-2 billion per year and approximately US $1 billion is spent on the revision of malfunctioning shunts (2). This may be a result of poor shunt design or a flawed approach to treatment.

Circulation theory rests on the assumption that the brain parenchyma is impermeable to water, and is therefore incapable of independently absorbing the CSF that accumulates in the ventricles. However, we have previously seen that the brain is, in fact, permeable to water due to the presence of aquaporin channels and other ion channels (3,4). This permeability of brain parenchyma to water and several other observations question the validity and applicability of circulation theory to design treatment strategies for hydrocephalus.

In brain tissue and in the ventricles, we see that osmotic gradients drive water diffusion in water permeable tissue. Alteration in osmolarity resulting from increase in the concentration of macromolecules and ions has been shown to increase the fluid content and hence the size of the ventricles (5-7). Any osmotic gradient between the ventricular or interstitial CSF and the blood is equilibrated with transport of water between the two compartments. Therefore, water movement into the ventricle is secondary to the presence of osmotic gradients due to excess macromolecules. Thus, water movement into and out of the ventricles is not independent but is dependent upon the presence and resolution of osmotic gradients due to increase or decrease in the macromolecular content (8).

Within this article, we review the role played by osmotic gradients and macromolecular ventricular clearance in hydrocephalus. Macromolecular clearance from the ventricles is a mechanism to establish the normal CSF osmolarity, and therefore ventricular volume. At least two primary pathways of macromolecular ventricular clearance have been studied: paravascular pathways (also known as lymphatic pathways) and olfactory lymphatic pathways.

In particular, we focus on the role played by efflux transporters, specifically p-gp (ABC-B1) in the pathogenesis of hydrocephalus. Efflux transporters are responsible for the transport and clearance of both endogenous (endobiotics) and exogenous (xenobiotics) substances. An understanding of these transporters is critical to designing effective pharmacological treatment for this problematic disorder.

**OSMOTIC GRADIENT AND ITS ROLE IN HYDROCEPHALUS**

Previously, hydrocephalus was thought to be a result of an imbalance between CSF production by the choroid plexus and absorption of CSF into the venous sinuses (9,10). Clinical and experimental data to substantiate circulation theory have remained inconclusive (11).

One of the fundamental assumptions of the circulation theory is that the brain parenchyma is impermeable to CSF, and is therefore incapable of absorbing the CSF accumulating within the ventricles. However, the brain parenchyma is permeable to water (12). The molecular basis of this permeability involves specific ion channels that permit water movement with ions as well as aquaporin channels, which permit the free movement of water without changing the ionic environment (3). Aquaporin channels are membrane proteins that have an ion trap and allow movement of water without allowing movement of ions. Several aquaporin channels (aquaporins 1, 4, and 9) are found in the brain tissues (13-15). Aquaporin 4 (AQP4) channels are found in the ependymal cells lining the lateral ventricles and on the end feet of astrocytes. These astrocytes, in particular, contact microvessels in the pereventricular white matter and the subpial region of the cerebral cortex (4). The distribution of AQP4 within the brain suggests that water freely moves through the brain parenchyma between the ventricles and vascular system.
As a consequence of water permeability in the brain tissues, osmotic gradients are established by the presence of relatively impermeable, regulated solutes in the ventricles. These gradients result in water transport from the blood plasma into the ventricular CSF (5,6). Driven by osmotic and hydrostatic gradients, water moves between blood plasma and CSF as blood flows through the microvasculature (7,11,16). Therefore, as the osmolarity of ventricular plasma and CSF as blood flows through the microvasculature increases within the cerebral ventricles, water movement into the ventricles increases, causing hydrocephalus.

Clinically, high levels of proteins such as thrombopoietin (17), ferritin (18), nerve growth factor (19), chondroitin sulfate proteoglycan (20), transforming growth factor beta 1 (21,22), transforming growth factor beta 2 (20), S-100 protein (23,24), glial fibrillary acidic protein (GFAP) (24), neuron specific enolase (NSE) (24), myelin basic protein (MBP) (24), and vascular endothelial growth factor (25) within ventricular CSF, which may contribute to an elevation in osmolarity, have been observed in patients with hydrocephalus. Additionally, it has been shown that brain edema results from hyponatremia, which is evidence that there is free movement of water from the plasma into the brain tissue (26).

There is substantial experimental evidence relating the osmolarity of the CSF to hydrocephalus. Evidence that an increase in CSF osmolarity leads to an increase in ventricular volumes has recently been shown through experiments in our laboratory. Dextran infused into the ventricles of rat brains in vivo over 12 days resulted in hydrocephalus, with increasing levels of CSF osmolarity corresponding to a proportional increase in ventricle volume (5,6). In other experiments, infusion of proteins FGF-2 (27) and thrombin (28) into the ventricles of animals led to the dilation of ventricles. Other investigators have confirmed the pivotal role that osmotic gradients play in the enlargement of the ventricles and development of hydrocephalus (29-31). A recent study demonstrated significantly faster entry of water from the blood plasma into the CSF with acute increase in CSF osmolarity, which subsequently led to an increase in intracranial pressure (7). These facts suggest that fluid transport from and to the ventricles is secondary to solute or macromolecular transport.

PATHWAYS FOR CLEARANCE OF MACROMOLECULES

Since osmotic gradients result in hydrocephalus and are caused by the presence of macromolecules in the ventricles, it is particularly important to understand ventricular clearance of macromolecules. We found that macromolecules infused into the ventricles are cleared through the brain parenchyma along the perivascular spaces and along the cribiform plate into the nose (paper being submitted for publication). These findings are consistent with the results of other authors (32-35). Rennels et al infused horseradish peroxidase (HRP) into the lateral ventricles and found that there was a rapid paravascular influx of HRP – a faster influx than can be expected from diffusion (33). The same group found that this transport of HRP through the paravascular pathways was limited by focal cerebral edema (36). Zhang et al injected India ink into cerebral white and gray matter and into the subarachnoid space and found that the tracer was transported along specific paravascular pathways (37). Further, subarachnoid injection resulted in transport of the tracer along the paravascular pathways as well as through the lymphatics in the nose. The observation that macromolecules or tracers in the ventricles are transported along paravascular pathways has been recently confirmed by observing the tracer movement using confocal microscopy (38) and magnetic resonance (MR) imaging (39). These pathways have been referred to as the glymphatic pathways or system (38,39). Zhang et al found that the particulate matter that was injected was rapidly and efficiently ingested by perivascular cells (37). These authors highlighted both the paravascular and the nasal lymphatic pathways in macromolecular clearance and their immunological significance (38).

LOCATION AND FUNCTION OF EFFLUX TRANSPORTERS

The regulation of transport of macromolecules into and out of the brain is vital to maintaining homeostasis and ensuring a proper environment for neural activity. There are a number of both endobiotic and xenobiotic compounds (Table 1) that have been documented to be cleared from the brain at the blood-brain barrier (BBB). Efflux transporters are located along the blood-brain barrier as well as blood-CSF barrier (BCSF) and play an important role in maintaining homeostasis of compounds and solutes in the brain milieu as well as the CSF (40). The brain capillary endothelial cells form a tight barrier and are characterized by the absence of any fenestrations (41). These anatomical features of the BBB restrict the paracellular leakage of endogenous or exogenous compounds from the brain into the capillaries (42). As a result, transcellular transport across the BBB and subsequent clearance by these efflux transporters is critical in the elimination of unwanted solutes from the brain (41). The two important classes of ac-
tive efflux transporters on the BBB are the solute transporter carrier family (SLC) (this family includes organic anion transporting polypeptides [OATP/SLCO] and organic anion transporters [OAT/SLC22A]) and ATP-binding cassette (ABC) transporters, in particular multidrug resistance-associated proteins and p-gp (41).

Members of the ABC transporter family, which include p-gp, MRP 1-6, and BRCP, have been shown to eliminate an abundance of macromolecular substrates from the brain including anticancer drugs, immunosuppression drugs, corticoids, analgesics, HIV protease inhibitors, cytokines, antidepressants, antibiotics, and diagnostic dyes, such as Rhodamine-123, just to name a few (43). Barbiturates, many of which are p-gp substrates (44), injected into the CSF compartments of dogs are rapidly cleared into the bloodstream (45). Cholecystokinin-A (CCK-A) and CCK-B have both been shown to be p-gp substrates (46). One study found that intraventricular injection of CCK-A led to less feeding in rats, presumably being cleared into the bloodstream and interacting with peripheral receptors (47).

Xenobiotics and other endobiotics are recognized by xenobiotic sensors also known as adopted “orphan” nuclear receptors (pregnane X receptor [PXR] and constitutive androstane receptor [CAR]) in the cytoplasm (48). Both nuclear receptors can be activated by endogenous ligands and a wide range of xenobiotics (49), which include a broad array of prescription drugs, herbal remedies, steroid hormones, bile salts, and vitamins (50). These nuclear receptors can then up-regulate the functional expression of p-gp (51). Inhibition of PXR and CAR activities could reduce p-gp expression, whereas activation of PXR and CAR can induce p-gp expression (50).

P-gp expression on the plasma membranes of the brain capillary endothelial cells (on the luminal or blood-side of the endothelial cell), pericytes, and astrocytes show that p-gp is expressed in all cells that make up the BBB (52). The paravascular pathways may clear macromolecules through the BBB, particularly by using efflux transporters located on the BBB (38). Specifically, p-gp is of great interest in this role due to the fact that it is the most abundant efflux transporter on the BBB and has broad substrate specificity (53). In addition, p-gp transporters are distributed along the pathways of the macromolecular clearance explained above, along the microvessels in the thalamus, hippocampus, cerebellar, and cerebral cortex from 22 weeks of gestation to adulthood (54). Therefore, we are going to focus the discussion on the role played by efflux transporters with a special emphasis on p-gp.

**P-GLYCOPROTEIN AND ITS ROLE IN THE PATHOPHYSIOLOGY OF HYDROCEPHALUS**

We hypothesize that impaired macromolecular clearance out of the brain will result in increased concentration of endobiotics or xenobiotics in the brain interstitium and ventricular fluid. This change will result in water in-

**TABLE 1. Examples of compounds cleared from the brain**

| Compound | Endogenous/Exogenous/xenobiotic |
|----------|---------------------------------|
| Amyloid-β (28) | 3′-azido-3′-deoxythymidine (107) |
| Cholecystokinin-A (47) | 2′,3′-dideoxyinosine (108) |
| Cholecystokinin-B (47) | Vinca Alkaloids (108) |
| Neuropeptide Y (88) | Doxorubicin (109) |
| Albumin (89) | Cyclosporin A (109) |
| Transferrin (89) | Digoxin (109) |
| Iron (90) | Methotrexate (109) |
| Dehydroepiandrosterone sulfate (91) | Pemetrexed (110) |
| Estrone-3-sulfate (92) | Prednisolone (110) |
| Creatinine (93) | Morphine (111) |
| GABA (94) | Dextran (83) |
| Leptin (95) | Amprenavir (112) |
| Guanidinoacetate (96) | Indinavir (113) |
| Taurine (97) | Verapamil (114) |
| L-Proline (98) | Phenobarbital (115) |
| Glycine (99) | Lamotrigine (116) |
| Taurocholic acid (99) | Felbamate (116) |
| Prostaglandin D2 (100) | Dantrolene (116) |
| L-Aspartic Acid (101) | Digoxin (117) |
| L-Glutamic Acid (102) | Rhodamine-123 (117) |
| Indoxyl Sulfate (102) | Nortriptyline (118) |
| Hippuric Acid (103) | D-serine (105) |
| 3-carboxy-4-methyl-5-propyl-2-furanpropanoic Acid (103) | Adenine (107) |
| Quinolinic Acid (103) | Adenosine (107) |
| 5-hydroxyindole Acetic Acid (103) | 17beta-estradiol-D-17beta-glucuronide (104) |
| Homovanillic Acid (103) | D-serine (105) |
| 3-hydroxyglutamic Acid (103) | Hypoxanthine (106) |
| Methylmalonic Acid (104) | Adenine (107) |
| 17beta-estradiol-D-17beta-glucuronide (104) | Adenosine (107) |
flux into the ventricles resulting in hydrocephalus. Optimal efflux transport and clearance of macromolecules prevents the development of hydrocephalus. Down-regulation or inhibition of the efflux transport will result in hydrocephalus, while up-regulation of the efflux transport will relieve hydrocephalus. We will examine the current evidence that supports this concept.

Inhibition and induction of p-gp has been shown to affect the amount of substrates that remain within the brain or enter it. Induction of p-gp at the BBB has been shown to decrease the concentration of such substrates in the brain extracellular fluid (55-59). Conversely, inhibition of p-gp on the BBB has been shown to increase substrate concentrations in the brain (60-64). Several studies point to the possible role of p-gp in diseases of the central nervous system including Alzheimer disease (65,66), Parkinson disease (65,66), Huntington’s disease (66), Creutzfeldt-Jakob’s disease (66), amyotrophic lateral sclerosis (66), and epilepsy (66). The role that p-gp plays in numerous neurodegenerative diseases is believed to be in part due to the protection that it provides at the BBB to maintain homeostasis in the brain (60-64). Several studies point to the possible role of p-gp in diseases of the central nervous system including Alzheimer disease (65,66), Parkinson disease (65,66), Huntington’s disease (66), Creutzfeldt-Jakob’s disease (66), amyotrophic lateral sclerosis (66), and epilepsy (66). The role that p-gp plays in numerous neurodegenerative diseases is believed to be in part due to the protection that it provides at the BBB to maintain homeostasis in the brain and protect it against toxic compounds. Its function along the BBB is believed to prevent the accumulation of potentially harmful compounds in the brain by actively removing them into the peripheral circulation (67).

The importance of macromolecular clearance in maintaining normal neurological function is exemplified by the pathophysiology of Alzheimer disease. Normally amyloid-β is cleared from the brain via efflux transporters on the BBB, particularly by p-gp and MRP1 (68). When amyloid-β is insufficiently cleared from the brain, toxic Aβ oligomeric and aggregated species accumulate in the brain, which results in Alzheimer disease (69). Manipulation of these efflux transporters can lead to either increased or decreased clearance of Aβ from the brain. Rifampicin and caffeine, which are two compounds that up-regulate p-gp activity, were shown to increase the clearance of Aβ from the brain (70). On the other hand, knockout of two efflux transporters p-gp and BCRP increased the amount of Aβ within the brain (71).

There is a considerable overlap of Alzheimer disease and normal pressure hydrocephalus, with some authors reporting nearly 50% of patients with probable NPH having evidence of AD (72). Several studies have shown that these two diseases co-exist, and the presence of amyloid plaques in the brain tissues of patients with normal pressure hydrocephalus is indicative of poor prognosis for successful treatment of hydrocephalus (71-75). Recently, positron emission tomography (PET) has been used to detect the presence of amyloid plaques in patients clinically suspected to have normal pressure hydrocephalus (76).

Macromolecules are transported out of the ventricles and the brain into the serum even in the presence of hydrocephalus. Clinical studies show that there are several endo-biotics that are cleared from CSF into the serum and these include S-100b, GFAP, NSE, and MBP. Vascular endothelial growth factor (VEGF) is elevated in CSF of patients with hydrocephalus (77). VEGF was increased several fold in the CSF in experimental chronic hydrocephalus and the increase was significantly correlated with ventricular volume (78). Excess VEGF in the CSF is known to decrease p-gp activity, thus contributing to hydrocephalus (79).

Experimental evidence in models of congenital hydrocephalus further supports the role played by p-gp in the pathogenesis. P-gp expression in the subcortical white matter and periventricular tissues (paravascular pathways) of H-Tx rats was absent when compared to normal animals (80). In another study (81), H-Tx rats were also found to have reduced nasal lymphatic clearance of CSF, suggesting that the paravascular/lymphatic clearance of CSF were impaired. In support of our experimental model of hydrocephalus, dextrans are known to be substrates of p-gp and they are distributed along both the olfactory pathways as well as the paravascular pathways (82).

One of the most common causes of hydrocephalus is intraventricular hemorrhage (IVH). IVH is a cause of significant morbidity and mortality as a complication of neonatal germinal matrix hemorrhage and adult intracerebral hemorrhage (83). IVH causes hydrocephalus in 25–50% of these individuals and results in additional damage to the brain (83). Despite the fact that the amount of blood in the ventricles plays a role in the development of hydrocephalus, it is not known why some patients develop hydrocephalus and some do not. The role played by p-gp as an efflux transporter can potentially explain this variability.

There is considerable variation of expression of pgp in general population. P-gp is the gene product of MDR1 (ABCB1). The MDR1 gene is subject to single nucleotide polymorphisms, which is associated with decreased function of p-gp between individuals (84). A well-known example of this variability affecting function is in relation to the opiate analgesics.
Mu opioid receptor agonists have identical target receptor affinities adjusted for dose (85). Despite this characteristic, individual opioids exhibit a marked variation in their ability to induce clinically-relevant analgesia despite equipotent mu opioid receptor doses administered systemically, a characteristic that is explained entirely on the basis of the affinity of p-gp for an individual opioid (analgesia is inversely proportional to the affinity of the p-gp efflux transporter for the substrate drug) (86). Hence, loperamide, a potent mu opioid receptor agonist, does not produce either euphoria or analgesia, being marketed over-the-counter in the USA as an antidiarrheal preparation, due to its local inhibition of gut motility (88). Evidence that loperamide has in vivo potent mu opioid agonist properties in the brain and that this effect is solely due to p-gp efflux has been clearly supported by pretreatment with a potent p-gp inhibitor prior to loperamide administration (87).

It is still unclear why some patients with IVH develop hydrocephalus and others do not. One of the possible explanations is that there are genetic differences between individuals in how well they clear the blood and the blood products from the ventricles. Based on the discussions above, we hypothesize that if a patient has a genetic variant with decreased functionality of p-gp, then the potential for eliminating macromolecules from the ventricles will be reduced in the presence of IVH, resulting in hydrocephalus.

In conclusion, hydrocephalus results from abnormal osmotic gradients that favor water transport into the ventricles. These abnormal gradients are due to a change in the macromolecular and ionic content in the ventricular CSF. Efflux transporters, in particular p-gp, play a key part in the clearance of macromolecules, both endogenous and exogenous, out of the ventricles and the brain, thus maintaining the milieu interior. We have summarized existing literature with reference to p-gp and provided a context for focusing on this transporter with regards to hydrocephalus. However, the details regarding the exact role played in hydrocephalus are yet to be clarified.

Funding None.

Ethical approval Not required.

Declaration of authorship SK conceived the paper and directed the review of the literature based on the prior work done by him on the osmotic model of hydrocephalus. Read, analyzed, and wrote the paper with other authors. MDT was primarily involved in collecting and reviewing the articles as directed by the lead author. Assisted in writing the paper. AGS was primarily involved in collecting and reviewing the articles as directed by the lead author. DBL conceived the paper from a pharmacological perspective and involved in the construction and writing of the paper as directed by the lead author. Assisted in writing the paper. MDT was primarily involved in collecting and reviewing the articles as directed by the lead author. AGS was primarily involved in collecting and reviewing the articles as directed by the lead author.

Competing interests All authors have completed the Unified Competing Interest form at www.cmj.hr (available on request from the corresponding author) and declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.

References
1 Facts about hydrocephalus: National Hydrocephalus Foundation. Available from: http://nhfonline.org/facts-about-hydrocephalus.htm. Accessed: August 7, 2014.
2 Simon TD, Riva-Cambrin J, Srivastava R, Bratton SL, Dean JM, Kestle JR, et al. Hospital care for children with hydrocephalus in the United States: Utilization, charges, comorbidities, and deaths. J Neurosurg Pediatr. 2008;1:131-7. Medline:18352782 doi:10.3171/ PED/2008/1/2/131
3 Agre P. Aquaporin water channels. Biosci Rep. 2004;24:127-63. Medline:16209125 doi:10.1007/s10540-005-2577-2
4 Agre P, Nielsen S, Ottersen OP. Towards a molecular understanding of water homeostasis in the brain. Neuroscience. 2004;129:849-50. Medline:15561402 doi:10.1016/j.neuroscience.2004.10.001
5 Krishnamurthy S, Li J, Schultz L, McAllister JP II. Intraventricular infusion of hyperosmolar dextran induces hydrocephalus: a novel animal model of hydrocephalus. Cerebrospinal Fluid Res. 2009;6:16. Medline:20003330 doi:10.1186/1743-8454-6-16
6 Krishnamurthy S, Li J, Schultz L, Jenrow KA. Increased CSF osmolarity reversibly induces hydrocephalus in the normal rat brain. Fluids and Barriers of the CNS. 2012;9:13. Medline:22784705 doi:10.1186/2045-8118-9-13
7 Klarica M, Mišić B, Vladić A, Radić M, Orešković D. “Compensated hyperosmolarity” of cerebrospinal fluid and the development of hydrocephalus. Neuroscience. 2013;248C:278-89. Medline:23806710 doi:10.1016/j.neuroscience.2013.06.022
8 Krishnamurthy S, Li J. New concepts in the pathogenesis of hydrocephalus. Trans Pediatr 2014;3(3):185-194. doi:10.3978/j.issn.2224-4336.2014.07.02
9 Mori K. Current concept of hydrocephalus: evolution of new classifications. Childs Nerv Syst. 1995;11:523-31. Medline:8529219 doi:10.1007/BF00822842
10 Rekate HL. The definition and classification of hydrocephalus: a personal recommendation to stimulate debate. Cerebrospinal Fluid Res. 2008;5:2. Medline:18217172 doi:10.1186/1743-8454-5-2
11 Oreskovic D, Klarica M. Development of hydrocephalus and classical hypothesis of cerebrospinal fluid hydrodynamics: Facts and illusions. Prog Neurobiol. 2011;94:238-58. Medline:21641963 doi:10.1016/j.pneaurobio.2011.05.005
12 Gato A, Moro JA, Alonso MI, Pastor JF, Represa JJ, Barbosa E. Chondroitin sulfate proteoglycan and embryonic brain enlargement in the chick. Anat Embryol (Berl). 1993;188:101-6. Medline:8214620 doi:10.1007/BF00191455
13 Kim JG, Son YJ, Yun CH, Kim Y, Il Nam-goong S, Park JH, et al.
thyroid transcription factor-1 facilitates cerebrospinal fluid formation by regulating aquaporin-1 synthesis in the brain. J Biol Chem. 2007;282:14923-31. Medline:17371871 doi:10.1074/jbc.M701411200

14 Tait MJ, Saadoun S, Bell BA, Papadopoulos MC. Water movements in the brain: role of aquaporins. Trends Neurosci. 2008;31:37-43. Medline:18054802 doi:10.1016/j.tins.2007.11.003

15 Zador Z, Bloch O, Yao X, Manley GT. Aquaporins: role in cerebral edema and brain water balance. Prog Brain Res. 2007;161:185-94. Medline:17618977 doi:10.1016/S0079-6123(06)61012-1

16 Marakovic J, Oreskovic D, Rados M, Vukic M, Jurjevic I, Chudy D, et al. Effect of osmolality on CSF volume during ventriculo-aqueductal and ventriculo-cisternal perfusions in cats. Neurosci Lett. 2010;484:93-7. Medline:20674671 doi:10.1016/j.neulet.2010.07.058

17 Reinhold A, Zhang J, Gessner R, Felderhoff-Mueser U, Obladen M, Dame C. High thrombopoietin concentrations in the cerebrospinal fluid of neonates with sepsis and intraventricular hemorrhage may contribute to brain damage. J Interferon Cytokine Res. 2007;27:137-45. Medline:17316141 doi:10.1089/jir.2006.0096

18 Suzuki H, Muramatsu M, Tanaka K, Fujiwara H, Kojima T, Taki W. Cerebrospinal fluid ferritin in chronic hydrocephalus after aneurysmal subarachnoid hemorrhage. J Neurol. 2006;253:1170-6. Medline:16649098 doi:10.1007/s00401-007-1038-4

19 Mashayekhi F, Salehi Z. Expression of nerve growth factor in cerebrospinal fluid of congenital hydrocephalic and normal children. Eur J Neurol. 2005;12:632-7. Medline:16053473 doi:10.1111/j.1468-1331.2005.00144.x

20 Chow LC, Soliman A, Zandian M, Danielpour M, Krueger RC Jr. Accumulation of transforming growth factor-beta2 and nitrated chondroitin sulfate proteoglycans in cerebrospinal fluid correlates with poor neurologic outcome in preterm hydrocephalus. Biol Neonate. 2005;88:1-11. Medline:15711035 doi:10.1159/000083945

21 Flood C, Akinwunmi J, Lagord C, Daniel M, Berry M, Jackowski A, et al. TGF β1 in the CSF of patients with subarachnoid hemorrhage: titers derived from exogenous and endogenous sources. J Cereb Blood Flow Metab. 2001;21:157-62. Medline:11176281 doi:10.1097/00004464-200102000-00007

22 Whitelaw A, Christie S, Popiel J. TGF β1: a possible signal molecule for posthemorrhagic hydrocephalus? Pediatr Res. 1999;46:576-80. Medline:10541321 doi:10.1203/00006450-199911000-00014

23 Beems T, Simons KS, van Geel WJA, de Reus HPM, Vos PE, Verbeek MM. Serum and CSF-concentrations of brain specific proteins in hydrocephalus. Acta Neurochir (Wien). 2003;145:37-43. Medline:12455260 doi:10.1007/s00701-002-1019-1

24 Sendrowski K, Sobaniec W, Sobaniec-Lotowska ME, Lewczuk PS. S-100 protein as marker of the blood-brain barrier disruption in children with internal hydrocephalus and epilepsy—a preliminary study. Rocz Akad Med Bialymst. 2004;49 Suppl 1:236-8. Medline:15638435

25 Heep A, Stoffel-Wagner B, Bartmann P, Benseler S, Schaller C, Gorneck P, et al. Vascular endothelial growth factor and transforming growth factor-beta1 are highly expressed in the cerebrospinal fluid of premature infants with posthemorrhagic hydrocephalus. Pediatr Res. 2004;56:768-74. Medline:15319463 doi:10.1203/01.PDR.0000141524.32142.53

26 Trinh-Trang-Tan MM, Cartron JP, Bankir L. Molecular basis for the dialysis disequilibrium syndrome: altered aquaporin and urea transporter expression in the brain. Nephrol Dial Transplant. 2005;20:1984-8. Medline:15985519 doi:10.1093/ndt/gfh677

27 Johansen CE, Szmydzynger-Chobodksa J, Chobodski A, Baird A, McMillan P, Stopa EG. Altered formation and bulk absorption of cerebrospinal fluid in FGF-2 induced hydrocephalus. Am J Physiol. 1999;277:R263-71. Medline:10409281

28 Gao F, Liu F, Chen Z, Hua Y, Keep RF, Xi G. Hydrocephalus after intraventricular hemorrhage: the role of thrombin. J Cereb Blood Flow Metab. 2014;34:489-94. Medline:24326390 doi:10.1038/jcbfm.2013.225

29 Lowery LA, Sive H. Initial formation of zebrafish brain ventricles occurs independently of circulation and requires the nageeoko and snakehead/atp1a1.1 gene products. Development. 2005;132:2057-67. Medline:15788456 doi:10.1242/dev.01791

30 Parvas M, Bueno D. The embryonic blood-CSF barrier has molecular elements to control e-csf osmolality during early CNS development. J Neurosci Res. 2010;88:1205-12. Medline:19937806

31 Klancar M, Oreskovic D, Kalousek M, Hat J, Mise B, Bulat M. Intracranial pressure response to application of hypertonic sucrose into cerebrospinal fluid by the microvolume exchange method in dogs. Neurol Croat. 1994;43:147-54.

32 Wagner HJ, Pilgrim CH, Brandl J. Penetration and removal of horseradish peroxidase injected into the cerebral spinal fluid: role of cerebral perivascular spaces, endothelium and microglia. Acta Neuropathol. 1974;27:299-315. Medline:4366438 doi:10.1007/BF00690695

33 Rennels ML, Gregory TF, Blaumanis OR, Fujimoto K, Grady PA. Evidence for a “paravascular” fluid circulation in the mammalian central nervous system, provided by the rapid distribution of tracer protein throughout the brain from the subarachnoid space. Brain Res. 1985;326:47-63. Medline:3971148 doi:10.1016/0006-8993(85)91383-6

34 Johnston M, Zakharov A, Papaiconomou C, Salmazi G, Armstrong D. Evidence of connections between cerebrospinal fluid and nasal lymphatic vessels in humans, non-human primates and other mammalian species. Cerebrospinal Fluid Res. 2004;1:2. Medline:15679948 doi:10.1186/1743-8454-1-2

35 Brinker T, Ludemann W, Berens VR, Samii M. Dynamic properties of lymphatic pathways for the absorption of cerebrospinal fluid. Acta Neurochir. 1999;141:899-905. Medline:9386783 doi:10.1007/s004010050738

36 Blaumanis OR, Rennels ML, Grady PA. Focal cerebral edema
Efflux transporters in the pathogenesis of hydrocephalus

48 Chan GNY, Iloque T, Cummins CL, Bendayan R. Regulation of p-glycoprotein and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. J Clin Pharmacol. 2007;47:566-78. Medline:17442683 doi:10.1177/0022371207299903

49 Urquhart BL, Tirona RG, Kim RB. Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. J Clin Pharmacol. 2007;47:566-78. Medline:17442683 doi:10.1177/0022371207299903

50 Moore LB, Maglich JM, McKee DD, Wisely B, Willson TM, Kliwer SA, et al. PregnanXreceptor (PXR), constitutive androstane receptor (CAR), and benzoate X receptor (BXR) define three pharmacologically distinct classes of nuclear receptors. Mol Endocrinol. 2002;16:977-86. Medline:11981033 doi:10.1210/ jend.16.5.0828

51 Miller DS. Regulation of P-glycoprotein and other ABC drug transporters at the blood brain barrier. Trends Pharmacol Sci. 2010;31:246-54. Medline:20417575 doi:10.1016/j.tips.2010.03.003

52 Bendayan R, Ronaldson PT, Gingeras D, Bendayan M. In situ localization of P-glycoprotein (ABCB1) in human and rat brain. J Histochem Cytochem. 2006;54:1159-67. Medline:16801529 doi:10.1369/jhc.5A8070.2006

53 Dolghih E, Jacobson MP. Predicting efflux ratios and blood-brain barrier penetration from chemical structure: combining passive permeability with active efflux by p-glycoprotein. ACS Chem Neurosci. 2013;4:361-7. Medline:23421687 doi:10.1021/cn3001922

54 Daood MJ, Tsai C, Ahbab-Barmada M, Watchko JF. ABC transporter (P-gp/ABCB1, MRP1/ABCC1, BCRP/ABCG2) expression in the developing human CNS. Neuropediatrics. 2008;39:211. Medline:19165709 doi:10.1055/s-0028-1103272

55 Chan GN, SaldiaV, Yang Y, Pang H, de Lannoy I, Bendayan R. In vivo induction of P-glycoprotein expression at the mouse blood-brain barrier: an intracerebral microdialysis study. Epilepsia Res. 2012;100:93-103. Medline:22342565 doi:10.1016/j.eplepsires.2012.01.012

56 Miller DS. Regulation of P-glycoprotein and other ABC drug transporters at the blood brain barrier. Trends Pharmacol Sci. 2010;31:246-54. Medline:20417575 doi:10.1016/j.tips.2010.03.003

57 Mullauer J, Kuntner C, Bauer M, Bankstahl JP, Müller M, Voskuyl RA, et al. Pharmacokinetic modeling of P-glycoprotein function at the rat and human blood-brain barriers studied with [R]-[11C] verapamil positron emission tomography. EJNMMI Res. 2012;2:58. Medline:23072492 doi:10.1186/2045-7383-2-58

58 Ang X, Cabrera RM, Li Y, Miller DS, Finnell RH. Functional regulation of P-glycoprotein at the blood-brain barrier in proton-coupled folate transporter (PCFT) mutant mice. FASEB J. 2013;27:1167-75. Medline:23221213 doi:10.1096/fj.12-218495

59 Bankstahl JP, Kuntner C, Abrahim A, Karch R, Stanek J, Wanek T, et al. Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with [R]-1C-verapamil and PET. J Nucl Med. 2008;49:1328-35. Medline:18632828 doi:10.2967/jnumed.008.1051235

60 O'Brien FE, Clarke G, Fitzgerald P, Dinan TG, Griffin BT, Cryan JF. Inhibition of P-glycoprotein enhances transport of imipramine.
across the blood-brain barrier: microdialysis studies in conscious freely moving rats. Br J Pharmacol. 2012;166:1333-43. Medline:2250926 doi:10.1111/j.1476-5381.2012.01858.x
61. Mehringer A, Karamustafa S, Klotz D, Kahl S, Konkimalla VB, Wang Y, et al. Inhibition of P-glycoprotein at the blood-brain barrier by phytochemicals derived from traditional Chinese medicine. Cancer Genomics Proteomics. 2010;7:191-205. Medline:20656985
62. Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos. 2000;28:655-60. Medline:10820137
63. Anderson BD, May MJ, Jordan S, Song L, Roberts MJ, Leggas M. Dependence of neflanavir brain uptake on dose and tissue concentrations of the selective P-glycoprotein inhibitor zosuquidar in rats. Drug Metab Dispos. 2006;34:653-9. Medline:16443546 doi:10.1124/dmd.105.006536
64. Kaddoumi A, Choi SU, Kinman L, Whittington D, Tsai CC, Ho RJ, et al. Inhibition of P-glycoprotein activity at the primate blood-brain barrier increases the distribution of neflanavir into the brain but not into the cerebrospinal fluid. Drug Metab Dispos. 2007;35:1459-62. Medline:17591677 doi:10.1124/dmd.107.016220
65. Bartels AL. Blood-brain barrier P-glycoprotein function in neurodegenerative disease. Curr Pharm Des. 2011;17:2727-71. Medline:21831040 doi:10.2174/1381612117940122
66. Rapposelli S, Digiacoimo M, Balsamo A. P-gp transporter and its role in neurodegenerative diseases. Curr Top Med Chem. 2009;9:209-17. Medline:19200006
67. Bendayan R, Lee G, Bendayan M. Functional expression and localization of PGP at the blood brain barrier. Microsc Res Tech. 2002;57:365-80. Medline:12112443 doi:10.1002/jemt.10099
68. Qosa H, Abuznait AH, Hill RA, Kaddoumi A, Enhanced brain amyloid-β clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer’s disease. J Alzheimers Dis. 2012;31:151-65. Medline:22504320
69. Bell RD, Zlokovic BV. Neurovascular mechanisms and blood–brain barrier disorder in Alzheimer’s disease. Acta Neuropathol. 2009;118:103-13. Medline:19319544 doi:10.1007/s00401-009-0522-3
70. Savolainen S, Paljarvi L, Vapalahdi M. Prevalence of Alzheimer’s disease in patients investigated for presumed normal pressure hydrocephalus: a clinical and neuropathological study. Acta Neurochir (Wien). 1999;141:849-53. Medline:10536721 doi:10.1007/s007010050386
71. Zhang W, Xiong H, Callaghan D, Liu H, Jones A, Pei K, et al. Blood-brain barrier transport of amyloid beta peptides in efflux pump knock-out animals evaluated by in vivo optical imaging. Fluids Barriers CNS. 2013;10:13. Medline:23432917 doi:10.1186/2045-8118-10-13
72. Savolainen S, Hurskainen H, Paljarvi L, Alafuzoff I, Vapalahdi M. Five year outcome of normal pressure hydrocephalus with or without a shunt: predictive value of the clinical signs, neuropsychological evaluation and infusion test. Acta Neurochir. 2002;144:515-23. Medline:12111484 doi:10.1007/s00701-002-0936-3
73. Bech RA, Juhrer M, Waldemar G, Klinken L, Gerrits F. Frontal brain and leptomeningeal biopsy specimens correlated with cerebrospinal fluid outflow resistance and B wave activity in patients suspected of normal pressure hydrocephalus. Neurosurgery. 1997;40:497-502. Medline:9055288
74. Ball MJ. Neurofibrillary tangles in the dementia of “normal pressure” hydrocephalus. Can J Neurol Sci. 1976;3:227-35. Medline:1000408
75. Hamilton R, Patel S, Lee EB, Jackson EM, Lopinto J, Arnold SE, et al. Lack of shunt response in suspected idiopathic normal pressure hydrocephalus with Alzheimer disease pathology. Ann Neurol. 2010;68:535-40. Medline:20687117 doi:10.1002/ana.22015
76. Rinne JO, Wong DF, Wolk DA, Leinonen V, Arnold SE, Buckley C, et al. 18 F Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid beta detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies. Acta Neuropathol. 2012;124:433-45. Medline:23053137 doi:10.1007/s00401-012-1051-z
77. Madsen JR, Shim JW, Abazi G, Fleming L, Fernholz B, Connors S, et al. VEGF-a is elevated in CSF of pediatric patients undergoing surgery for hydrocephalus. Cerebrospinal Fluid Res. 2009;6 Suppl:S13. doi:10.1186/1743-8454-6-S1-513
78. Dombrowski SM, Leichliter A, Deshpande A, Dingwall C, Leibson Z, Luciano MG. Hydrocephalus induced ischemia relating to VEGF-R2 and blood vessel density in hippocampus. Cerebrospinal Fluid Res. 2006;3 suppl:S20. doi:10.1186/1743-8454-3-S1-S20
79. Hawkins BT, Sykes DB, Miller DS. Rapid, reversible modulation of blood brain barrier p-glycoprotein transport activity by vascular endothelial growth factor. J Neurosci. 2010;30:1417-25. Medline:20107068 doi:10.1523/JNEUROSCI.5103-09.2010
80. Kuwahara S, Sada Y, Moriki T, Yamane T, Hara H. Spatial and temporal expression of P-glycoprotein in the congenitally hydrocephalic HTX rat brain. Pathol Res Pract. 1996;192:496-507. Medline:8832757 doi:10.1016/S0344-0338(96)80018-5
81. Rammling M, Madan M, Paul L, Behnam B, Pattisapu JV. Evidence for reduced lymphatic CSF absorption in the H-Tx rat hydrocephalus model. Cerebrospinal Fluid Res. 2008;5:15. Medline:18025964 doi:10.1186/1743-8454-5-15
82. Watson PM, Paterson JC, Thom G, Ginnman U, Lundquist S, Webster CI. Modeling the endothelial blood-CNS barriers: a method for the production of robust in vitro models of the rat blood-brain barrier and blood-spinal cord barrier. BMC Neurosci. 2013;14:59. Medline:23773766 doi:10.1186/1471-2202-14-59
83. Strahle J, Garton HJL, Maher CO, Muraszko KM, Keep RF, Xi G. Mechanisms of hydrocephalus after neonatal and adult intraventricular hemorrhage. Transl Stroke Res. 2012;3 Suppl 1:25-38. Medline:23976902 doi:10.1007/s12975-012-0182-9
Efflux transporters in the pathogenesis of hydrocephalus

Kimchi-Sarfaty C, Marple AH, Shinar S, Kimchi AM, Scavo D, Roma MI, et al. Ethnicity related polymorphisms and haplotypes in the human ABCB1 gene. Pharmacogenet Genomics. 2007;8:29-39. Medline:17187507 doi:10.2217/14624168.1.1.29

Yaksh TL, Wallace MS. Opioids, analgesia, and pain management. In: Bruntun LL, Chabner BA, Knollman BC. Goodman & Gilman's the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill Professional; 2011. p. 481-525.

Hassan HE, Myers AL, Coop A, Eddington ND. Differential involvement of P-glycoprotein (ABCB1) in permeability, tissue distribution, and antinociceptive activity of methadone, buprenorphine, and diprenorphine: in vitro and in vivo evaluation. J Pharm Sci. 2009;98:4928-40. Medline:19370547 doi:10.1002/jps.21770

Sadeque AJ, Wandel C, He H. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther. 2000;68:231-7. Medline:11014404 doi:10.1067/mcp.2000.109156

Kastin AJ, Akerstrom V. Nonsaturable entry of neuropeptide Y into brain. Am J Physiol. 1999;276:E479-82. Medline:10070013

Zhang Y, Pardridge WM. Rapid transferrin efflux from brain to blood across the blood-brain barrier. J Neurochem. 2001;79:110-8. Medline:11595763 doi:10.1046/j.1471-4159.2001.00540.x

McCarthy RC, Park YH, Kosman DJ. sAPP modulates iron efflux from brain microvascular endothelial cells by stabilizing the ferrous iron exporter ferroportin. EMBO Rep. 2014;15:809-15. Medline:24867889 doi:10.15252/embr.201338064

Asaba H, Hosoya K, Takanaga H, Ohtsuki S, Tamura E, Takizawa T, et al. Characterization of the efflux transport of 17beta-estradiol-D-3-sulfate at the blood-brain barrier in rats. Life Sci. 2000;67:2699-711. Medline:11059866 doi:10.1016/S0022-3207(00)00861-4

Tachikawa M, Kasai Y, Takahashi M, Fujinawa J, Kitaichi K, Terasaki T, et al. The blood-cerebrospinal fluid barrier is a major pathway of cerebral creatinine clearance: involvement of transporter-mediated process. J Neurochem. 2008;107:432-42. Medline:18752645 doi:10.1111/j.1471-4159.2008.05641.x

Kakee A, Takanaga H, Terasaki T, Naito M, Tsuruo T, Sugiyama Y. Efflux of a suppressive neurotransmitter, GABA, across the blood-brain barrier. J Neurochem. 2001;79:110-8. Medline:11595763 doi:10.1046/j.1471-4159.2001.00540.x

Kurrimbux D, Gaffen Z, Farrell CL, Martin D, Thomas SA. The involvement of the blood-brain and the blood-cerebrospinal fluid barriers in the distribution of leptin into and out of the rat brain. Neuroscience. 2004;123:527-36. Medline:14698759 doi:10.1016/j.neuroscience.2003.08.061

Tachikawa M, Fujinawa J, Takahashi M, Kasai Y, Fukaya M, Sakai K, et al. Expression and possible role of creatine transporter in the brain and at the blood-cerebrospinal fluid barrier as a transporting protein of guanidinoacetate, an endogenous convulsant. J Neurochem. 2008;107:678-8. Medline:18761709 doi:10.1111/j.1471-4159.2008.05652.x

Chung SJ, Ramanathan VK, Bredt CM, Giacomini KM. Saturable disposition of taurine in the rat cerebrospinal fluid. J Pharmacol Exp Ther. 1996;276:676-82. Medline:8632336

Takanaga H, Tokuda N, Ohtsuki S, Hosoya K, Terasaki T. ATA2 is predominantly expressed as system A at the blood-brain barrier and acts as brain-to-blood efflux transport for L-proline. Mol Pharmacol. 2002;61:1289-96. Medline:12021389 doi:10.1124/mol.61.6.1289

Kitazawa T, Terasaki T, Suzuki H, Kakee A, Sugiyama Y. Efflux of taurocholic acid across the blood-brain barrier: interaction with cyclic peptides. J Pharmacol Exp Ther. 1998;286:890-5. Medline:9694947

Tachikawa M, Tsuji K, Yokoyama R, Higuchi T, Ozeki G, Yashiki A, et al. A clearance system for prostaglandin D2, a sleep-promoting factor, in cerebrospinal fluid: role of the blood-cerebrospinal barrier transporters. J Pharmacol Exp Ther. 2012;343:608-16. Medline:22931759 doi:10.1124/jpet.112.197012

Hosoya K, Sugawara M, Asaba H, Terasaki T. Blood-brain barrier produces significant efflux of L-aspartic acid but not D-aspartic acid: in vivo evidence using the brain efflux index method. J Neurochem. 1999;73:1206-11. Medline:10469113 doi:10.1046/j.1471-4159.1999.0731206.x

Ohtsuki S, Asaba H, Takanaga H, Deguchi T, Hosoya K, Otogiri M, et al. Role of blood-brain barrier organic anion transporter 3 (OAT3) in the efflux of indoxyl sulfate, a uremic toxin: its involvement in neurotransmitter metabolite clearance from the brain. J Neurochem. 2002;83:57-66. Medline:12358729 doi:10.1046/j.1471-4159.2002.01108.x

Sauer SW, Opp S, Mahringer A, Kaminiski MM, Thiel C, Okun JG, et al. Glutarcicudina type I and methylamioncicudia: simulation of cerebral import and export of accumulating neurotoxic dicarboxylic acids in in vitro models of the blood-brain barrier and the choroid plexus. Biochim Biophys Acta. 2010;1802:552-60. Medline:20302929 doi:10.1016/j.bbadis.2010.03.003

Sugiyama D, Kusuhara H, Shiota Y, Abe T, Meier PJ, Sekine T, et al. Characterization of the efflux transport of 17beta-estradiol-D-17beta-glucuronide from the brain across the blood-brain barrier. J Pharmacol Exp Ther. 2001;298:316-22. Medline:11408557

Kasai Y, Tachikawa M, Hirose S, Akanuma S, Hosoya K. Transport systems of serine at the brain barriers and in brain parenchymal cells. J Neurochem. 2011;118:304-13. Medline:21770

Isakovic AJ, Abbott NJ, Redzic ZB. Brain to blood efflux transport of adenosine: blood-brain barrier studies in the rat. J Neurochem. 2004;90:272-86. Medline:15228584 doi:10.1111/j.1471-
107 Takasawa K, Terasaki T, Suzuki H, Sugiyama Y. In vivo evidence for carrier-mediated efflux transport of 3’-azido-3’-deoxythymidine and 2’,3’-dideoxyinosine across the blood-brain barrier via a probenecid-sensitive transport system. J Pharmacol Exp Ther. 1997;281:369-75. Medline:9103519

108 Tsuji A. P-glycoprotein-mediated efflux transport of anticancer drugs at the blood-brain barrier. Ther Drug Monit. 1998;20:588-90. Medline:9780140 doi:10.1097/00007691-199810000-00024

109 Li L, Agarwal S, Elmquist WF. Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate. Drug Metab Dispos. 2013;41:659-67. Medline:23297298 doi:10.1124/dmd.112.049254

110 Karssen AM, Meijer OC, van der Sandt IC, De Boer AG, De Lange EC, De Kloet ER. The role of the efflux transporter P-glycoprotein in brain penetration of prednisolone. J Endocrinol. 2002;175:251-60. Medline:12379510 doi:10.1677/joe.0.1750251

111 Xie R, Hammarlund-Udenaes M, de Boer AG, de Lange EC. The role of P-glycoprotein in blood-brain barrier transport of morphine: transcortical microdialysis studies in mdr1a (−/−) and mdr1a (+/+ ) mice. Br J Pharmacol. 1999;128:563-8. Medline:10516633 doi:10.1038/sj.bjp.0702804

112 Polli JW, Jarrett JL, Studenberg SD, Humphreys JE, Dennis SW, Brouwer KR, et al. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm Res. 1999;16:1206-12. Medline:10468021 doi:10.1023/A:1018941328702

113 Hamidi M. Central nervous system distribution kinetics of indinavir in rats. J Pharm Pharmacol. 2007;59:1077-85. Medline:17725849 doi:10.1211/jpp.59.8.0004

114 Bauer M, Zeitlinger M, Karch R, Matznelser P, Stanek J, Jäger W, et al. Pgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data. Clin Pharmacol Ther. 2012;91:227-33. Medline:22166851 doi:10.1038/clpt.2011.217

115 Potschka H, Fedrowitz M, Löscher W. P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats. Neurosci Lett. 2002;327:173-6. Medline:12113905 doi:10.1016/S0304-3940(02)00423-8

116 Xiao G, Black C, Hetu G, Sands E, Wang J, Caputo R, et al. Cerebrospinal fluid can be used as a surrogate to assess brain exposures of breast cancer resistance protein and P-glycoprotein substrates. Drug Metab Dispos. 2012;40:779-87. Medline:22266779 doi:10.1124/dmd.111.043703

117 de Lange EC, de Boch G, Schinkel AH, de Boer AG, Breimer DD. BBB transport and P-glycoprotein functionality using MDR1A (−/−) and wild-type mice. Total brain versus microdialysis concentration profiles of rhodamine-123. Pharm Res. 1998;15:1657-65. Medline:9833984 doi:10.1023/A:1011988024295

118 Jensen BP, Roberts RL, Vyas R, Bonke G, Jardine DL, Begg EJ. Influence of ABCB1 (P-glycoprotein) haplotypes on nortriptyline pharmacokinetics and nortriptyline-induced postural hypotension in healthy volunteers. Br J Clin Pharmacol. 2012;73:619-28. Medline:21999196 doi:10.1111/j.1365-2125.2011.04126.x